Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03516695 · ClinicalTrials.gov registry record
RadioEmbolization for the ADvancement of Y90 Glass Microspheres Registry
A clinical trial, sponsored by Boston Scientific Corporation.
- Terminated
- Registry status
- 95
- Enrollment target
NCT03516695 is a clinical trial that was terminated before completion, run by Boston Scientific Corporation. The registered enrollment target is 95 participants.
The verdict
NCT03516695 was terminated before completion, sponsored by Boston Scientific Corporation.
- TERMINATED
- Registry status
- 95 participants
- Enrollment target
Study Summary
This study is a non-interventional, observational, prospective, and global participant data registry. The study will collect effectiveness and safety data from approximately 1000 participants with liver cancers treated with TheraSphere® in a real-life setting from multiple centers globally. The absorbed dose to tumor and normal tissue will be calculated using the Simplicit90Y™ software in the subgroup of hepatocellular carcinoma (HCC) participants.
Interventions
- DEVICE TheraSphere®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 95 participants |
| Start Date | 2018-02-23 |
| Est. Completion | 2018-12-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03516695
The ClinicalTrials.gov registry entry for NCT03516695 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 95 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Scientific Corporation, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TheraSphere® is the first listed.
NCT03516695 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03516695 about?
NCT03516695 is a clinical study titled "RadioEmbolization for the ADvancement of Y90 Glass Microspheres Registry". This study is a non-interventional, observational, prospective, and global participant data registry. The study will collect effectiveness and safety data from approximately 1000 participants with liver cancers treated with TheraSphere® in a real-life setting from multiple centers globally. The abso...
What is the current status of trial NCT03516695?
This trial is currently terminated. The enrollment target is 95 participants. The study started on 2018-02-23. Estimated completion is 2018-12-12.
What interventions are being tested in trial NCT03516695?
The interventions under investigation include: TheraSphere® (DEVICE).
Who is sponsoring clinical trial NCT03516695?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.